CJC-1295 and Ipamorelin: Two Complementary Growth Hormone Peptides
CJC-1295 Ipamorelin is one of the most researched peptide combinations in growth hormone biology, combining two distinct mechanisms to produce synergistic effects on growth hormone release. CJC-1295 is a synthetic analogue of Growth Hormone Releasing Hormone (GHRH) — the hypothalamic peptide that signals the pituitary gland to produce and release growth hormone. Ipamorelin is a Growth Hormone Releasing Peptide (GHRP) — a ghrelin receptor agonist that stimulates growth hormone release through a completely different receptor pathway. The combination of GHRH analogue and GHRP targets two independent stimulatory pathways simultaneously, producing effects that exceed either compound alone in research models.
With 1,600 monthly Australian searches, CJC-1295 + Ipamorelin is the most queried growth hormone peptide stack in the domestic market, reflecting genuine research and community interest in this well-characterised combination.
How CJC-1295 Works
CJC-1295 (without DAC) acts as a GHRH analogue, binding to GHRH receptors on pituitary somatotroph cells and stimulating growth hormone synthesis and release. The version without Drug Affinity Complex (DAC) has a shorter half-life than CJC-1295 with DAC, producing a pulsatile GH release pattern that more closely mimics physiological GH secretion rather than a sustained elevation. This pulsatile pattern is relevant in research because it better preserves the normal temporal patterns of GH and IGF-1 signalling.
CJC-1295 amplifies the existing GH pulse amplitude — it works with the body's own GH release cycles rather than overriding them. This means its effects are partly dependent on the underlying GH secretion pattern of the research subject, with the compound augmenting rather than substituting for endogenous pulsatile release.
How Ipamorelin Works
Ipamorelin is a selective GHRP that stimulates GH release through ghrelin receptor (GHS-R) activation. Unlike earlier generation GHRPs (GHRP-2, GHRP-6), Ipamorelin has high selectivity for the GH-stimulating effect without significantly elevating cortisol, prolactin, or other hormones that earlier GHRPs non-selectively raised. This selectivity makes it a cleaner research tool for isolating the GH pathway from confounding hormonal effects.
Because CJC-1295 and Ipamorelin work through different receptor pathways (GHRH receptors vs ghrelin receptors), combining them produces additive to potentially synergistic GH release — essentially pressing both accelerators simultaneously. Research has confirmed that the combination produces substantially greater GH release than either compound alone, explaining why the stack has become the dominant approach in growth hormone peptide research.
Research Applications of the CJC-1295 Ipamorelin Stack
Research applications of CJC-1295 + Ipamorelin focus primarily on growth hormone-mediated effects: body composition research (muscle protein synthesis, fat metabolism), sleep quality (GH is primarily released during slow-wave sleep), recovery and repair (GH promotes IGF-1 production which mediates many anabolic effects), and ageing biology (GH/IGF-1 axis declines with age and is of interest in longevity research).
Optic Labs supplies CJC-1295 (No DAC) + Ipamorelin as a pre-combined 10mg blend for researchers, independently tested for both components and supplied with a certificate of analysis confirming purity of each peptide in the combination.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC has a much longer half-life (approximately 8 days) due to its albumin-binding modification, producing sustained GH elevation. CJC-1295 without DAC has a shorter half-life and produces pulsatile GH release more similar to physiological patterns. Most research protocols prefer the No DAC version for its more physiological release profile.
Why is Ipamorelin preferred over earlier GHRPs?
Ipamorelin has high selectivity for GH stimulation without significantly raising cortisol, prolactin, or ACTH — side effects associated with earlier GHRPs like GHRP-2 and GHRP-6. This selectivity makes Ipamorelin a cleaner research tool for studying the GH pathway specifically.
How does combining CJC-1295 and Ipamorelin improve outcomes?
The two compounds work through different receptor pathways — GHRH receptors (CJC-1295) and ghrelin receptors (Ipamorelin) — producing additive to synergistic GH release when combined. Research has shown the combination produces substantially greater GH elevation than either compound alone.
Is CJC-1295 Ipamorelin legal in Australia?
CJC-1295 and Ipamorelin are not scheduled substances in Australia and can be purchased for research purposes. They are not approved therapeutic agents and cannot be sold for human therapeutic use.
This article is for educational and research purposes only. Optic Labs products are intended for research use only and are not for human consumption. Always consult a qualified healthcare professional before considering any compounds.